Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Soria

Showing results (1-10 of 280) with videos related to

Pageof 28
Sort By:
Translational Andrology and Urology|April 13, 2018
How to assess and improve health-related quality of life in bladder cancer patientsFrancesco Soria, Paolo Gontero
European Urology|December 12, 2025
The Winding Road to High-quality Transurethral Resection of the BladderFrancesco Soria, Paolo Gontero
European Urology|April 17, 2019
Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialFrancesco Soria, Paolo Gontero
European Urology Focus|January 26, 2024
Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti's Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019Francesco Soria, Paolo Gontero
European Urology|February 8, 2021
Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical TrialFrancesco Soria, Paolo Gontero
European Urology|March 12, 2025
Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia and Alberto Briganti's Letter to the Editor re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531-49Paolo Gontero, Francesco Soria,
European Urology Oncology|July 30, 2022
Intermediate-risk Non-muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?Francesco Soria, Paolo Gontero
The Journal of Urology|May 28, 2020
Editorial CommentFrancesco Soria, Paolo Gontero
Translational Andrology and Urology|January 29, 2019
Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiersFrancesco Soria, Shahrokh F Shariat
Current Opinion in Urology|March 25, 2020
Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice?Francesco Soria, Andrea Giordano, Paolo Gontero
Pageof 28

Showing results (1-10 of 280) with videos related to

Sort By:
Pageof 28
Translational Andrology and Urology|April 13, 2018
How to assess and improve health-related quality of life in bladder cancer patientsFrancesco Soria, Paolo Gontero
European Urology|December 12, 2025
The Winding Road to High-quality Transurethral Resection of the BladderFrancesco Soria, Paolo Gontero
European Urology|April 17, 2019
Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialFrancesco Soria, Paolo Gontero
European Urology Focus|January 26, 2024
Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti's Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019Francesco Soria, Paolo Gontero
European Urology|February 8, 2021
Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical TrialFrancesco Soria, Paolo Gontero
European Urology|March 12, 2025
Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia and Alberto Briganti's Letter to the Editor re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531-49Paolo Gontero, Francesco Soria,
European Urology Oncology|July 30, 2022
Intermediate-risk Non-muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?Francesco Soria, Paolo Gontero
The Journal of Urology|May 28, 2020
Editorial CommentFrancesco Soria, Paolo Gontero
Translational Andrology and Urology|January 29, 2019
Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiersFrancesco Soria, Shahrokh F Shariat
Current Opinion in Urology|March 25, 2020
Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice?Francesco Soria, Andrea Giordano, Paolo Gontero
Pageof 28